2 results match your criteria: "Cleveland Clinic (J.P.[Affiliation]"
Pomalidomide for Epistaxis in Hereditary Hemorrhagic Telangiectasia.
N Engl J Med
September 2024
From Massachusetts General Hospital, Boston (H.A.-S.); University of North Carolina, Chapel Hill (R.S.K.), and RTI International, Research Triangle Park (D.M., L.B., B.A.C., S.M.T.) - both in North Carolina; Mayo Clinic, Rochester, MN (V.N.I.); University of Pennsylvania, Philadelphia (A.M.P.); Medical College of Wisconsin, Milwaukee (J.E.D.); Johns Hopkins University, Baltimore (C.R.W.), and CureHHT, Monkton (M.C.) - both in Maryland; University of Utah, Salt Lake City (K.J.W.); University of California, San Francisco, San Francisco (M.B.C.); University of Florida, Gainesville (M.S.Z.); University of California, San Diego, La Jolla (J.Y.Z.); and Taussig Cancer Center and Lerner Research Institute (K.R.M.), Cleveland Clinic (J.P., L.W., K.R.M.), Cleveland.
Article Synopsis
- Hereditary hemorrhagic telangiectasia (HHT) is a genetic disorder that leads to severe nosebleeds and related health issues, primarily affecting patients' quality of life due to iron-deficiency anemia from frequent epistaxis.
- A study was conducted where 144 participants were given either pomalidomide or a placebo for 24 weeks to assess the drug's effectiveness in reducing nosebleed severity and improving quality of life, with results favoring the pomalidomide group.
- The results showed that those taking pomalidomide experienced a greater decrease in bleeding scores and improved quality-of-life measures, although there were some additional side effects observed in the pomalidomide group.
Correlation Between Blue Fundus Autofluorescence and SD-OCT Measurements of Geographic Atrophy in Dry Age-Related Macular Degeneration.
Am J Ophthalmol
October 2024
From The Tony and Leona Campane Center for Excellence in Image-Guided Surgery and Advanced Imaging Research, Cleveland Clinic (J.P.E., C.M., S.Y., H.C., Y.C., G.K., R.A., J.W., V.W., M.B., J.R., S.K.S.), Cleveland, Ohio, USA; Cole Eye Institute, Cleveland Clinic (J.P.E., C.M., S.Y., H.C., Y.C., G.K., R.A., J.W., V.W., M.B., J.R., S.K.S.), Cleveland, Ohio, USA.
Article Synopsis
- The study compared fundus autofluorescence (FAF) and optical coherence tomography (OCT) measurements of geographic atrophy (GA) to evaluate the effectiveness of avacincaptad pegol (ACP) treatment in a clinical trial called GATHER1.
- A post hoc analysis showed a strong correlation (r = 0.93) between FAF and OCT measurements, indicating that both methods provided similar results in assessing GA area.
- The OCT showed a significant reduction in GA growth between ACP and sham groups at 12 and 18 months, confirming that OCT can be a reliable method for measuring GA in clinical settings.